Unlike other classes of HDACs, the deacetylation activity of class IV HDAC is relatively weak, and as such, HDAC11 inhibitors might have a greater prospective in obesity treatment because of their relatively fewer side effects (51, 55). The gene discussed is HDAC9; the disease is obesity disorder.